• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genprex Inc (NQ: GNPX )

    0.6901 -0.0199 (-2.80%)
    Streaming Delayed Price Updated: 10:21 AM EDT, Aug 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Genprex Inc

    < Previous 1 2 3 4 Next >
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Management to Participate in Two Upcoming Conferences
    Via Investor Brand Network
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $4M Registered Direct Offering
    Via Investor Brand Network
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Inks Deal with University of Pittsburgh for Exclusive License to Diabetes Technology
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Gene Therapy Treatment Data to be Presented at Upcoming International Diabetes Conference
    Via Investor Brand Network
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial, Licenses Additional Technology from University of Pittsburgh
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present Gene Therapies for Cancer and Diabetes at Upcoming Conference
    Via Investor Brand Network
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Upcoming Investor, Industry Conferences
    Via Investor Brand Network
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CFO to Present Pioneering Gene Therapies at Upcoming Conference
    Via Investor Brand Network
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures New Patent, Critical Protection for REQORSA(TM) Combination Therapy
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial to Higher Dose
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in June Investor Conferences
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Investor Conference
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CMO to Participate at 33rd Annual Cancer Progress Conference as Expert Panelist
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Shareholder Letter, 2022 Corporate Update
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in April 2022 Conferences
    Via Investor Brand Network
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Opens Acclaim-2 Clinical Trial for Patient Enrollment
    Via Investor Brand Network
    Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
    From Genprex, Inc.
    Via Business Wire
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at 2022 BIO Europe Spring Investor Conference
    Via Investor Brand Network
    Genprex to Participate in Upcoming Investor Conference in March
    From Genprex, Inc.
    Via Business Wire
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Dosing of First Patient in Acclaim-1 Clinical Trial
    Via Investor Brand Network
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate at February Investor Conferences
    Via Investor Brand Network
    Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes
    From Genprex, Inc.
    Via Business Wire
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Oncology Programs, Further Explore Use of ONCOPREX(R) Nanoparticle Delivery System
    Via Investor Brand Network
    Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer
    From Genprex, Inc.
    Via Business Wire
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Accelerate Opening of Acclaim-1 Clinical Trial Sites
    Via Investor Brand Network
    Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer
    From Genprex, Inc.
    Via Business Wire
    Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes
    From Genprex, Inc.
    Via Business Wire
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Oncology R&D Pipeline to Include Small Cell Lung Cancer
    Via Investor Brand Network
    Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer
    From Genprex, Inc.
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.